Zoetis Inc. (ZTS): Price and Financial Metrics

Zoetis Inc. (ZTS): $186.49

-0.11 (-0.06%)

POWR Rating

Component Grades














  • Quality is the dimension where ZTS ranks best; there it ranks ahead of 94.81% of US stocks.
  • The strongest trend for ZTS is in Stability, which has been heading down over the past 31 weeks.
  • ZTS ranks lowest in Momentum; there it ranks in the 34th percentile.

ZTS Stock Summary

  • With a market capitalization of $88,591,466,407, Zoetis Inc has a greater market value than 97.31% of US stocks.
  • ZTS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 371.84 -- higher than 90.27% of US-listed equities with positive expected earnings growth.
  • In terms of volatility of its share price, ZTS is more volatile than only 2.21% of stocks we're observing.
  • Stocks that are quantitatively similar to ZTS, based on their financial statements, market capitalization, and price volatility, are ANTM, MDLZ, INFY, TJX, and CI.
  • ZTS's SEC filings can be seen here. And to visit Zoetis Inc's official web site, go to www.zoetis.com.

ZTS Price Target

For more insight on analysts targets of ZTS, see our ZTS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $185.00 Average Broker Recommendation 1.52 (Moderate Buy)

ZTS Stock Price Chart Interactive Chart >

Price chart for ZTS

ZTS Price/Volume Stats

Current price $186.49 52-week high $187.32
Prev. close $186.60 52-week low $131.28
Day low $185.88 Volume 204,572
Day high $187.00 Avg. volume 1,936,676
50-day MA $174.17 Dividend yield 0.54%
200-day MA $163.88 Market Cap 88.54B

Zoetis Inc. (ZTS) Company Bio

Zoetis Inc. discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. The company was founded in 1952 and is based in Florham Park, New Jersey.

ZTS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$186.49$68.27 -61%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Zoetis Inc. To summarize, we found that Zoetis Inc ranked in the 30th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Zoetis Inc, consider:

  • The company has produced more trailing twelve month cash flow than 81.53% of its sector Healthcare.
  • The business' balance sheet suggests that 8% of the company's capital is sourced from debt; this is greater than just 24.53% of the free cash flow producing stocks we're observing.
  • ZTS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 41.08% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Zoetis Inc? See GILD, HAPP, CRL, DHR, and GMED.

ZTS Latest News Stream

Event/Time News Detail
Loading, please wait...

ZTS Latest Social Stream

Loading social stream, please wait...

View Full ZTS Social Stream

Latest ZTS News From Around the Web

Below are the latest news stories about Zoetis Inc that investors may wish to consider to help them evaluate ZTS as an investment opportunity.

Pet Medication Market to Witness Massive Growth by Zoetis, Merial, Bayer

Latest released the research study on Global Pet Medication Market, offers a detailed overview of the factors influencing the global business scope. Pet Medication Market research report shows the latest market insights with upcoming trends and breakdown of the products

OpenPR | June 17, 2021

Cat Vitamins Market Analysis by Size, Share, Growth, Trends up to 2027 | Zoetis, Bayer, Zesty Paws

The report titled Global Cat Vitamins Market is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Cat Vitamins market. The

OpenPR | June 17, 2021

Dog Vitamins Market Analysis by Emerging Growth Factors and Revenue Forecast to 2027 | Zoetis, Bayer, Zesty Paws

The report titled Global Dog Vitamins Market is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Dog Vitamins market. The

OpenPR | June 17, 2021

Anti-worm Medication Market 2021 2027 | Growth Dynamics, Revenue Outlook and Opportunities Forecast | Bayer, Boehringer Ingelheim, Zoetis

The authors of the report have deeply researched key areas of the global Anti-worm Medication market and provided verified market findings and reliable recommendations to help players ensure long-term growth. LOS ANGELES, United States: The global Anti-worm Medication Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical []

Jumbo News | June 17, 2021

Hedge Funds Cashing Out Of Zoetis Inc (ZTS)

No summary available.

Insider Monkey | June 17, 2021

Read More 'ZTS' Stories Here

ZTS Price Returns

1-mo 5.95%
3-mo 20.16%
6-mo 16.39%
1-year 36.96%
3-year 121.24%
5-year 302.12%
YTD 13.03%
2020 25.76%
2019 55.71%
2018 19.45%
2017 35.55%
2016 12.64%

ZTS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ZTS Dividend History

Continue Researching ZTS

Here are a few links from around the web to help you further your research on Zoetis Inc's stock as an investment opportunity:

Zoetis Inc (ZTS) Stock Price | Nasdaq
Zoetis Inc (ZTS) Stock Quote, History and News - Yahoo Finance
Zoetis Inc (ZTS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.3717 seconds.